136 related articles for article (PubMed ID: 35816242)
1. Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma.
Guo JC; Lin CC; Hsu CL; Huang TC; Kuo HY; Lin CY; Lien MY; Cheng AL; Hsu CH
Esophagus; 2022 Oct; 19(4):693-701. PubMed ID: 35816242
[TBL] [Abstract][Full Text] [Related]
2. The effects of altered DNA damage repair genes on mutational processes and immune cell infiltration in esophageal squamous cell carcinoma.
Yuan H; Qing T; Zhu S; Yang X; Wu W; Xu K; Chen H; Jiang Y; Zhu C; Yuan Z; Zhang T; Jin L; Suo C; Lu M; Chen X; Ye W
Cancer Med; 2023 Apr; 12(8):10077-10090. PubMed ID: 36708047
[TBL] [Abstract][Full Text] [Related]
3. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
[TBL] [Abstract][Full Text] [Related]
4. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Teo MY; Seier K; Ostrovnaya I; Regazzi AM; Kania BE; Moran MM; Cipolla CK; Bluth MJ; Chaim J; Al-Ahmadie H; Snyder A; Carlo MI; Solit DB; Berger MF; Funt S; Wolchok JD; Iyer G; Bajorin DF; Callahan MK; Rosenberg JE
J Clin Oncol; 2018 Jun; 36(17):1685-1694. PubMed ID: 29489427
[TBL] [Abstract][Full Text] [Related]
5. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
[TBL] [Abstract][Full Text] [Related]
6. Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.
Chen G; Zhu YJ; Chen J; Miao F; Wu N; Song Y; Mao BB; Wang SZ; Xu F; Chen ZM
Neoplasma; 2022 Dec; 69(6):1314-1321. PubMed ID: 36264776
[TBL] [Abstract][Full Text] [Related]
7. Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature.
Zhang P; Wen B; Gong J; Liu Z; Zhang M; Zhou G; Zhang L; Zhang Z
Environ Toxicol; 2024 May; 39(5):2803-2816. PubMed ID: 38287713
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.
Lu J; Du L; Lei X; Zhang Z
Cancer Med; 2023 May; 12(10):11334-11343. PubMed ID: 36951584
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
[TBL] [Abstract][Full Text] [Related]
11. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
12. Low expression of PRDM5 predicts poor prognosis of esophageal squamous cell carcinoma.
Guo J; Yang Q; Wei S; Shao J; Zhao T; Guo L; Liu J; Chen J; Wang G
BMC Cancer; 2022 Jul; 22(1):745. PubMed ID: 35799142
[TBL] [Abstract][Full Text] [Related]
13. The prognostic role of FZD6 in esophageal squamous cell carcinoma patients.
Zhang J; Wang JL; Zhang CY; Ma YF; Zhao R; Wang YY
Clin Transl Oncol; 2020 Jul; 22(7):1172-1179. PubMed ID: 31748958
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
15. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.
Chen YX; Wang ZX; Jin Y; Zhao Q; Liu ZX; Zuo ZX; Ju HQ; Cui C; Yao J; Zhang Y; Li M; Feng J; Tian L; Xia XJ; Feng H; Yao S; Wang FH; Li YH; Wang F; Xu RH
Cancer Cell; 2023 May; 41(5):919-932.e5. PubMed ID: 37059106
[TBL] [Abstract][Full Text] [Related]
16. Risk model based on genes regulating the response of tumor cells to T-cell-mediated killing in esophageal squamous cell carcinoma.
Zhang X; Yu C; Zhou S; Zhang Y; Tian B; Bian Y; Wang W; Lin H; Wang LW
Aging (Albany NY); 2024 Feb; 16(3):2494-2516. PubMed ID: 38305770
[TBL] [Abstract][Full Text] [Related]
17. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
[TBL] [Abstract][Full Text] [Related]
18. Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1.
Oshima K; Kato K; Ito Y; Daiko H; Nozaki I; Nakagawa S; Shibuya Y; Kojima T; Toh Y; Okada M; Hironaka S; Akiyama Y; Komatsu Y; Maejima K; Nakagawa H; Onuki R; Nagai M; Kato M; Kanato K; Kuchiba A; Nakamura K; Kitagawa Y
Cancer Sci; 2022 Mar; 113(3):1018-1027. PubMed ID: 34962019
[TBL] [Abstract][Full Text] [Related]
19. Intronic polymorphisms in genes LRFN2 (rs2494938) and DNAH11 (rs2285947) are prognostic indicators of esophageal squamous cell carcinoma.
Wang J; Wang Q; Wei B; Zhou Y; Qian Z; Gao Y; Chen X
BMC Med Genet; 2019 May; 20(1):72. PubMed ID: 31053115
[TBL] [Abstract][Full Text] [Related]
20. [Establishment and validation of prognostic risk score model for esophageal squamous cell carcinoma based on immune related genes].
Liu HR; Jiang GZ; Xin D; Yang YL; Fan QX; Meng XR; Li SL; Liu Y; Xia J; Wang F
Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):666-673. PubMed ID: 34289558
[No Abstract] [Full Text] [Related]
[Next] [New Search]
